Peptides for Blood Sugar Management & Glycaemic Control

Peptides regulate blood sugar through several interconnected mechanisms:

1. Incretin Enhancement (GLP-1 & GIP Pathways) GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are natural incretin hormones that account for 50-70% of the insulin response to a meal. In type 2 diabetes, this incretin effect is impaired. Peptide agonists restore and amplify incretin signalling, producing glucose-dependent insulin secretion — meaning they stimulate insulin only when blood sugar is elevated, dramatically reducing hypoglycaemia risk compared to older diabetes medications.

2. Glucagon Suppression Excessive glucagon production by pancreatic alpha cells drives hepatic glucose output in type 2 diabetes. GLP-1 agonists suppress inappropriate glucagon secretion, reducing fasting blood glucose and post-meal spikes.

3. Beta Cell Preservation Preclinical evidence suggests GLP-1 agonists may protect and even regenerate pancreatic beta cells through anti-apoptotic and proliferative effects. This is significant because progressive beta cell failure is the core pathology of type 2 diabetes.

4. Gastric Emptying Modulation GLP-1 agonists slow gastric emptying, reducing the rate at which glucose enters the bloodstream after meals. This blunts post-prandial glucose spikes — one of the earliest and most damaging features of metabolic dysfunction.

5. Central Appetite Regulation GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety. Peptide agonists reduce caloric intake by 20-35%, driving weight loss that further improves insulin sensitivity. This dual metabolic benefit — blood sugar control plus weight loss — is unique to this class.

6. Amylin Co-Secretion Effects Amylin is a peptide hormone co-secreted with insulin from beta cells. It slows gastric emptying, suppresses glucagon, and promotes satiety. In type 2 diabetes (and especially type 1), amylin secretion is deficient. Amylin analogues restore this missing signal.